<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78641">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02081690</url>
  </required_header>
  <id_info>
    <org_study_id>AC-055-310</org_study_id>
    <nct_id>NCT02081690</nct_id>
  </id_info>
  <brief_title>A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain</brief_title>
  <acronym>ORCHESTRA</acronym>
  <official_title>A Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the French, Italian and Spanish Versions of the PAH-SYMPACT™</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multi-center, open-label, single-arm, Phase 3b psychometric validation study.

      Primary objectives: To evaluate the psychometric characteristics of reliability and
      construct validity of the French, Italian and Spanish versions of the PAH-SYMPACT™.

      To evaluate the ability of the French, Italian and Spanish versions of the PAH SYMPACT™ to
      detect change.

      Secondary objective: To assess the safety of macitentan in patients with pulmonary arterial
      hypertension (PAH).

      Exploratory objective: To explore the effects of macitentan on PAH symptoms and their impact
      (as measured by the PAH-SYMPACT™) in patients with PAH in France, Italy and Spain.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment
  </why_stopped>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psychometric validation of the French, Italian and Spanish versions of the PAH-SYMPACT™ patient-reported outcome tool</measure>
    <time_frame>From Screening Visit (Visit 1) to End of Treatment (EOT) Visit (Visit 4, Week 16)</time_frame>
    <description>Evaluation of the psychometric characteristics of reliability and construct validity of the PAH-SYMPACT, and the ability of the PAH-SYMPACT to detect change.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the PAH-SYMPACT symptom and impact scores</measure>
    <time_frame>From Baseline Visit (Visit 2, Day 1) to Week 8 and from Baseline Visit to Week 16</time_frame>
    <description>Change in the PAH-SYMPACT symptom and impact scores assessed by the PAH-SYMPACT questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the safety of macitentan</measure>
    <time_frame>From Screening Visit (Visit 1) to End of Treatment (EOT) Visit (Visit 4, Week 16)</time_frame>
    <description>Frequency of treatment-emergent adverse events (AEs); AEs leading to premature discontinuation of study drug; treatment emergent serious adverse events (SAEs); change from Baseline to Week 16 in vital signs; treatment-emergent liver aminotransferase abnormalities (＞3, ＞5, and ＞8 X upper limit of normal) associated or not with total bilirubin ＞2 X upper limit of normal; treatment-emergent hemoglobin abnormality (≦100 g/L and ≦80 g/L).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Macitentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Macitentan tablet, dose of 10 mg, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Macitentan</intervention_name>
    <description>Macitentan tablet, dose of 10 mg, once daily</description>
    <arm_group_label>Macitentan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent prior to initiation of any study-mandated procedure.

          2. Patients with symptomatic PAH in WHO Functional Class (FC) II or III.

          3. Patients with PAH belonging to one of the following subgroups of the Dana Point
             Clinical Classification Group 1:

               1. Idiopathic, or,

               2. Heritable, or,

               3. Drug or toxin induced, or,

               4. Associated with one of the following:

             i. Connective tissue disease, ii. Congenital heart disease with simple
             systemic-to-pulmonary shunt at least 1 year after surgical repair, iii. HIV
             infection.

          4. Documented hemodynamic diagnosis of PAH by right heart catheterization - performed at
             any time prior to Screening showing:

               1. Resting mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg and,

               2. Resting pulmonary vascular resitance (PVR) &gt; 240 dyn.s.cm-5 and,

               3. Pulmonary capillary wede pressure (PCWP) or left ventricular end diastolic
                  pressure (LVEDP) ≤ 15 mmHg.

          5. 6-minute walk distance (6MWD) ≥ 150 m at Screening.

          6. Able to fluently speak and read the local language.

          7. Men or women aged 18-80; women of childbearing potential (as defined below) must:

               1. Have a negative serum pregnancy test at Screening and a negative urine pregnancy
                  test at Baseline and agree to perform monthly serum pregnancy tests, and,

               2. Agree to use two reliable methods of contraception in parallel, from Screening
                  Visit 1 until 1 month after study drug discontinuation (see details below).

                    -  A female is considered to have childbearing potential unless she meets at
                       least one of the following criteria:

                         -  Previous bilateral salpingo and/or oophorectomy, or hysterectomy.

                         -  Premature ovarian failure confirmed by a specialist.

                         -  Pre-pubescence, XY genotype, Turner syndrome, uterine agenesis.

                         -  Postmenopausal, defined as 12 consecutive months with no menses
                            without an alternative medical cause.

                    -  Of the two contraceptive methods that must be used, one must be from Group
                       1, and one must be from Group 2, defined as follows:

                         -  Group 1: Oral, implantable, transdermal or injectable hormonal
                            contraceptives, intrauterine devices, female sterilization (tubal
                            ligation or non surgical sterilization, e.g., permanent contraception
                            with Essure procedure), or partner's sterilization (vasectomy). If a
                            hormonal contraceptive is chosen from this group, it must be taken for
                            at least 1 month prior to enrollment. Alternatively, if the Essure
                            procedure is chosen as a contraceptive method, a hysterosalpingogram
                            must have been performed to confirm correct location of the
                            microinserts and tubal occlusion (as per manufacturer's
                            recommendations).

                         -  Group 2: Female or male condoms, diaphragm or cervical cap, any of
                            them in combination with a spermicide.

                    -  Sexual abstinence, rhythm methods, or contraception by the partner alone
                       are not considered as acceptable methods of contraception for this study.

        Exclusion Criteria:

          1. Known moderate-to-severe obstructive lung disease (i.e., forced expiratory volume in
             one second [FEV1] &lt; 80 % of predicted, with FEV1 / forced vital capacity [FVC] &lt; 70%)
             or known significant chronic lung disease diagnosed by chest imaging (e.g.,
             interstitial lung disease, emphysema).

          2. Known moderate-to-severe restrictive lung disease (i.e., total lung capacity [TLC] &lt;
             60% of predicted value).

          3. Hemoglobin &lt; 100g/L at Screening.

          4. Serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) &gt; 3 X
             upper limit of the normal range (ULN) at Screening.

          5. Patients undergoing dialysis.

          6. Systolic blood pressure (SBP) &lt; 90 mmHg at Screening.

          7. Body weight &lt; 40 kg at Screening.

          8. Known concomitant life-threatening diseases with a life expectancy of &lt; 12 months.

          9. Treatment with ERAs within 3 months prior to Visit 2, or scheduled to receive any of
             these compounds, other than macitentan, during the trial.

         10. Treatment with intravenous or subcutaneous prostacyclin or prostacyclin analogs
             within 3 months prior to Visit 2, or scheduled to receive any of these compounds
             during the trial.

         11. Treatment with soluble guanylate cyclase stimulator (riociguat) within 3 months prior
             to Visit 2, or scheduled to receive riociguat during the trial.

         12. Patients who changed the dose of or discontinued phosphodiesterase type-5 inhibitor
             (PDE5i), inhaled prostacyclin analogues, or calcium channel blockers within 3 months
             prior to Visit 2.

         13. Initiation of diuretics within 1 week prior to the Baseline period.

         14. Patients on oral diuretics in whom the dose has not been stable for at least 1 week
             prior to the Baseline period.

         15. Treatment with cytochrome P4500 (CYP) 3A inducers within 4 weeks prior to Visit 2.

         16. Recently started (&lt; 8 weeks prior to Visit 2) or planned cardio-pulmonary
             rehabilitation program based on exercise.

         17. Females who are lactating or pregnant (positive Screening or Baseline pregnancy test)
             or plan to become pregnant during the study.

         18. Known hypersensitivity to macitentan or its excipients or drugs of the same class.

         19. Treatment with another investigational drug within 3 months prior to Visit 2.

         20. Any known factor or disease that might interfere with treatment compliance, study
             conduct or interpretation of the results such as drug or alcohol dependence or
             psychiatric disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loïc Perchene</last_name>
    <role>Study Director</role>
    <affiliation>Actelion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital de Haut Levêque</name>
      <address>
        <city>Bordeaux</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Albert Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille - Hôpital Cardiologique</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Pradel</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux de Brabois</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42227</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Larrey</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi di Bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Venere</name>
      <address>
        <city>Bari</city>
        <zip>70131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant'Orsola</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U.C. Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milan Sacco Hospital</name>
      <address>
        <city>Milan</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AORN Azienda Ospedaliera dei Colli</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ambulatorio Scompenso Cardiaco e Trapiant</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Fisiologia clinica - CNR</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Per La Diagnosi E La Cura Dell'Ipertensione Polmonare</name>
      <address>
        <city>Roma</city>
        <zip>00186</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Immunologia Clinica B-PGRM Centro di Riferimento per la Sclerosi Sistemica</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;S. Maria di Cà Foncello&quot;</name>
      <address>
        <city>Treviso</city>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Insular Gran Canarias</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Islas Canarias</state>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Val Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Bilbao</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr Negrin</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>7010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospita General U. Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 26, 2016</lastchanged_date>
  <firstreceived_date>March 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAH-SYMPACT</keyword>
  <keyword>psychometric instrument</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macitentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
